Australia and New Zealand’s most promising haematology researchers now have a golden chance to step into the future of clinical trials and translational medicine—because applications for the prestigious ALLG HSANZ Clinical Trials Fellowship 2026 are officially open!
Jointly offered by the Australasian Leukaemia & Lymphoma Group (ALLG) and the Haematology Society of Australia and New Zealand (HSANZ), this competitive Fellowship is designed to ignite careers in blood cancer research by supporting early-career clinicians in leading innovative, patient-focused clinical trials.
What Does the Fellowship Offer?
This Fellowship delivers a $70,000 funding package over 12 months, giving the selected Fellow an immersive opportunity to work within ALLG’s active and influential clinical trials ecosystem. The focus? Advancing treatments for blood cancers like leukaemia, lymphoma, and myeloma—and ultimately improving patient lives.
But that’s not all. Fellows will also:
- Collaborate with renowned researchers and clinicians
- Gain expertise in trial design, implementation, and patient-reported outcomes
- Build critical networks for a long-term research career.
Why You Should Apply?
According to ALLG CEO Delaine Smith, this Fellowship is about more than funding—it’s about creating future leaders in blood cancer research. If you’re an early-career clinician or researcher passionate about improving outcomes in haematology, this could be your launching pad into a meaningful research-driven career.
Apply: https://www.allg.org.au/allg-hsanz-clinical-trials-fellowship-applications-now-open/
Application Deadline
The last date to apply for the ALLG HSANZ Clinical Trials Fellowship 2026 is 27 July 2025.
Follow Us
